138 related articles for article (PubMed ID: 22768658)
1. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
[TBL] [Abstract][Full Text] [Related]
2. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
3. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
Kappelgaard AM; Mikkelsen S; Knudsen TK; Fuchs GS
J Pediatr Endocrinol Metab; 2011; 24(7-8):489-96. PubMed ID: 21932587
[TBL] [Abstract][Full Text] [Related]
4. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
Adachi M
J Pediatr Endocrinol Metab; 2013; 26(11-12):1105-10. PubMed ID: 23843576
[TBL] [Abstract][Full Text] [Related]
5. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
Müller J; Skakkebaek NE; Jacobsen BB; Keller E; Heinrich U; Hartmann K; Hokken-Koelega AC; Delemarre van de Waal HA
Horm Res; 1999; 51 Suppl 3():109-12. PubMed ID: 10592453
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
Pawlikowska-Haddal A
Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
[TBL] [Abstract][Full Text] [Related]
7. Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.
Hokken-Koelega A; Keller A; Rakov V; Kipper S; Dahlgren J
ISRN Endocrinol; 2011; 2011():803948. PubMed ID: 22363887
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens.
Rohrer TR; Winter F; Qvist M; Kappelgaard AM
Expert Opin Drug Deliv; 2013 Dec; 10(12):1603-12. PubMed ID: 24073645
[TBL] [Abstract][Full Text] [Related]
9. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients.
Pfützner A; Hartmann K; Winter F; Fuchs GS; Kappelgaard AM; Rohrer TR
Clin Ther; 2010 Oct; 32(11):1918-34. PubMed ID: 21095487
[TBL] [Abstract][Full Text] [Related]
10. Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.
Maggio MC; Vergara B; Porcelli P; Corsello G
Ital J Pediatr; 2018 Sep; 44(1):113. PubMed ID: 30261918
[TBL] [Abstract][Full Text] [Related]
11. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: results from an open-label, user survey of everyday use.
Dahlgren J; Veimo D; Johansson L; Bech I
Curr Med Res Opin; 2007 Jul; 23(7):1649-55. PubMed ID: 17559757
[TBL] [Abstract][Full Text] [Related]
12. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
Stanhope R; Buchanan C; Butler G; Costigan C; Dunger D; Greene S; Hoey H; Hughes I; Kelnar C; Kirk J; Komulainen J; Lowry M; Warner J
J Pediatr Endocrinol Metab; 2001 Jun; 14(6):735-40. PubMed ID: 11453523
[TBL] [Abstract][Full Text] [Related]
13. Developments in administration of growth hormone treatment: focus on Norditropin® Flexpro®.
Yuen KC; Amin R
Patient Prefer Adherence; 2011 Mar; 5():117-24. PubMed ID: 21448295
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone therapy with a new delivery system.
Jørgensen JT; Susgaard S
Indian J Pediatr; 1991; 58 Suppl 1():43-50. PubMed ID: 1824374
[TBL] [Abstract][Full Text] [Related]
15. Adherence to growth hormone therapy in children and its potential barriers.
Mohseni S; Heydari Z; Qorbani M; Radfar M
J Pediatr Endocrinol Metab; 2018 Jan; 31(1):13-20. PubMed ID: 29216008
[TBL] [Abstract][Full Text] [Related]
16. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
17. Status of long-acting-growth hormone preparations--2015.
Høybye C; Cohen P; Hoffman AR; Ross R; Biller BM; Christiansen JS;
Growth Horm IGF Res; 2015 Oct; 25(5):201-6. PubMed ID: 26187188
[TBL] [Abstract][Full Text] [Related]
18. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
[TBL] [Abstract][Full Text] [Related]
19. The role of growth hormone device optimization in patient-reported outcomes: real-world evidence from South Korea.
Lee JE; Lee KH; Park MJ; Yang S; Kim EY; Rhie YJ; Jung MH; Yang A; Kim SH; Chung LY; Ko SY; Lee YJ; Nedjatian N; Chung WY
Expert Rev Med Devices; 2021 Jan; 18(1):91-106. PubMed ID: 33307881
[TBL] [Abstract][Full Text] [Related]
20. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
Colmenares A; González L; Gunczler P; Lanes R
J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
